Promising Covid Immunity Shot Stalled, LA Times Reports
In this article
We’re tracking the latest on the coronavirus outbreak and the global response. Sign up here for our daily newsletter on what you need to know.
A promising solution to temporarily prevent the coronavirus before a vaccine arrives has faced resistance from the U.S. government and drugmakers, according to an investigation by the Los Angeles Times.
Doctors and experts say an upper-arm shot using the antibody-rich blood plasma of Covid-19 survivors could inoculate people against the virus for months, but federal officials and companies have failed to act, the newspaper said.
Federal officials have twice rejected requests to discuss the proposal and pharmaceutical companies have declined to design or manufacture the shots even as they acknowledge the likely efficacy of the plan, the Times reported. Michael Joyner, a Mayo Clinic researcher who leads a program sponsored by the Food and Drug Administration to capitalize on coronavirus antibodies from Covid-19 survivors called the inaction a “lost opportunity.”
66,627 in U.S.Most new cases today
-6% Change in MSCI World Index of global stocks since Wuhan lockdown, Jan. 23
-1.088 Change in U.S. treasury bond yield since Wuhan lockdown, Jan. 23
4.4% Global GDP Tracker (annualized), June